XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe
19.11.2019 15:00:00 EET | Business Wire | Press release
Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/
(Graphic: Business Wire)
Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, has added to climate insecurity around the globe. All these factors have elevated the urgency of bringing the importance of preserving these precious ecosystems to the forefront of international discourse. Knowledge of the full biodiversity must be unlocked so that private companies, corporations, governments, individuals, local communities, and indigenous people who have demonstrated a commitment to preserving the rainforests will be empowered to sustain rainforests rather than destroy them.
The Rainforest XPRIZE will reward teams that can develop effective new technology to capture the true biological diversity of rainforests and further layer additional data to show the value of protecting the natural resources within them. The current methods used to identify and catalogue biodiversity, including in situ human-led studies, remote sensing by satellites or radar, or sophisticated spectroscopy, cannot operate to scale and gather the data necessary to understand the full ecosystem wealth of rainforests in sustainable ways. The competition accelerates a new bioeconomy, while also engaging indigenous and local communities, as well as local academic institutions in developing the solution. The Rainforest XPRIZE is a call-to-action to help save rainforests through the development and implementation of transformative, scalable, and affordable technology.
Anousheh Ansari, CEO of XPRIZE, said, “Amid our 25th anniversary as an organization, it is fitting that we add to our legacy by introducing a prize that will challenge the best and brightest to develop transformative technology to incentivize the preservation of rainforests worldwide, not only for our generation, but those to follow.”
“Despite their importance in supporting life on Earth, rainforests are undervalued because we simply do not yet know everything that exists in this ancient ecosystem,” said Executive Director of the Rainforest XPRIZE Jyotika Virmani, Ph.D. “I’m excited to see the innovative technologies that will emerge from this competition and give us a better assessment of the incredible biodiversity. Our goal is for the Rainforest XPRIZE to provide new understanding and reveal the true potential of the standing forest, allowing local communities to lead the way for all of us to live in harmony with these magnificent rainforests.”
The teams of the Rainforest XPRIZE will develop sophisticated technologies to inventory rainforest biodiversity faster, affordably, and in unprecedented detail in challenging harsh environments, delivering insights to support the sustainable use and well-being of the standing forest. Interdisciplinary teams can use emerging technologies such as robotics, remote sensing, data analysis, artificial intelligence, and machine learning to survey biodiversity, deal with the challenges of a harsh environment, and demonstrate that these ecosystems are worth preserving.
Specifically, the winning team will survey biodiversity in at least three stories of a rainforest (emergent, canopy, understory, and forest floor) in eight hours to produce the most comprehensive biodiversity assessment and utilize this and other data to produce the greatest number of insights in 48 hours. Insights may include, but are not limited to, new ecological dependencies, biodiversity and climate connectivity, anthropological findings, or even sustainable societal interactions with the forest.
The competition includes seven months for team registration and three months for initial technical document submission. A total prize purse of $10M will be awarded throughout the lifespan of the prize, including up to $500K in bonus prizes for innovative approaches to species identification. Milestone prizes will also be awarded equally for up to 10 final teams that advance through the semi-finals.
Throughout the life cycle of the competition and following the grand prize awards ceremony, XPRIZE will work to support and scale the impact of the teams’ work and promote education around rainforest preservation.
The Rainforest XPRIZE originated from Future of Forests Impact Roadmap. The Future of Forests Impact Roadmap identified six areas for breakthroughs that could usher in a preferred future for the world’s forests, one in which forests live in harmony in an environment that balances a healthy ecosystem with humanity’s changing needs, including economic growth, social progress, and political stability.
The deadline for teams to register through the XPRIZE website is June 30, 2020. Beginning July 1, 2020 to September 23, 2020 teams can request late registration, that will be at the discretion of XPRIZE. For more information, and to register your intent to compete, visit rainforest.xprize.org.
XPRIZE
XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005397/en/
Contact information
Katherine Schelbert
katherine.schelbert@xprize.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
